Please login to the form below

Not currently logged in

Healthineers’ COVID-19 antibody test launches in EU

Test can measure levels of neutralising antibodies in the blood

Siemens Healthineers has launched a COVID-19 test in Europe that can measure the levels of neutralising antibodies in the blood.

The SARS-CoV-2 IgG Antibody Test (sCOVG) has the ability to detect neutralising antibodies and reports quantitative results, measuring the levels present in a person’s blood sample.

Healthineers announced today that the sCOVG test has now achieved a CE mark, meaning that it can be marketed in the EU.

The medical technology company also announced that it has submitted an emergency use authorisation (EUA) application for the test to the US Food and Drug Administration (FDA).

Neutralising antibody levels are an important indicator of immune response to infectious diseases, including COVID-19. This type of antibody is capable of neutralisation, ie, the process of blocking the virus from infecting more cells.

Healthineers added in a statement that the sCOVG test could help to understand the effectiveness of COVID-19 vaccines, some of which could soon score regulatory approval.

By measuring neutralising antibody levels, the test could give an indication of the level of immunity that is provided by a vaccine for the SARS-CoV-2 virus, which causes COVID-19.

“Healthcare providers can feel confident that our test will help them determine whether a patient's immune system is producing the right antibodies to stop or prevent COVID-19 infection,” said Deepak Nath, president of laboratory diagnostics at Siemens Healthineers.

In July, Healthineer’s SARS-CoV-2 Total (COV2T) test proved the most effective out of four COVID-19 antibody tests evaluated in a comparative study conducted by Public Health England and Oxford University.

Aside from the COV2T test, the researchers evaluated Abbott’s SARS-CoV-2 Immunoassay, DiaSorin’s LIAISON SARSCoV-2 S1/S2 IgG and Roche’s Elecsys Anti-SARS-CoV-2.

For each test, the researchers calculated the sensitivity and specificity values, which were then compared to the performance target set by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of 98% across both criteria.

The Healthineers test came out on top, with a sensitivity value of 98.1% and a specificity value of 99.9%, proving more effective than the assays from Abbott, Roche and Diasorin.

It was also the only test to meet the target set by the MHRA across both specificity and sensitivity values, with the other three tests only meeting the specificity targets.

Article by
Lucy Parsons

19th November 2020

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....